Details for New Drug Application (NDA): 021861
✉ Email this page to a colleague
NDA 021861 describes PATANASE, which is a drug marketed by Novartis and is included in one NDA. Additional details are available on the PATANASE profile page.
The generic ingredient in PATANASE is olopatadine hydrochloride. There are seventeen drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the olopatadine hydrochloride profile page.
The generic ingredient in PATANASE is olopatadine hydrochloride. There are seventeen drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the olopatadine hydrochloride profile page.
Summary for 021861
| Tradename: | PATANASE |
| Applicant: | Novartis |
| Ingredient: | olopatadine hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 021861
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SPRAY, METERED;NASAL | Strength | 0.665MG/SPRAY **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Apr 15, 2008 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
